India's Hetero Labs, Cipla get approval to make Gilead's Covid-19 drug remdesivir
Gilead signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan to expand the supply of its Covid-19 treatment.
India's drug regulator has given Hetero Labs and Cipla Ltd the green light to manufacture and market their generic version of Gilead Sciences Inc's experimental Covid-19 treatment remdesivir, the Indian pharmaceutical companies said on Sunday.
The drug, which will be marketed under the brand name Covifor, will likely be priced at Rs5,000-6,000 rupees for a 100 milligram dose, Hetero said.
India's Cipla said its generic version of remdesivir will be called Cipremi.
The Drug Controller General of India (DCGI) was not immediately available for comment.
Gilead Sciences Inc signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan to expand the supply of its Covid-19 treatment.
The pacts allow Jubilant Life Sciences Ltd, Cipla, Hetero Labs, Mylan NV and Ferozsons Laboratories Ltd to make and sell the drug in 127 countries.
Indian drugmaker Zydus Cadila said last week it signed a non-exclusive licensing pact with Gilead Sciences to manufacture and market remdesivir.
The UAE is on track to flattening the Covid-19 curve. Offices,... READ MORE
Some KT readers suggest a negative Covid test result is not being... READ MORE
The vlogger, who is known by the name Prince Jack Abood (PJA),... READ MORE
UAE residents and visitors should have received a Covid-negative... READ MORE
He says 'we should be proud of our people and celebrate their success ... READ MORE
Travellers can apply for a permit through an 'exit registration... READ MORE
All passengers coming from Pakistan to Dubai on Emirates flights must ... READ MORE
Residents are urged to follow all preventive measures put in place by ... READ MORE